Participants in the Phase 2, placebo-controlled, OCEAN(a)-DOSE trial of olpasiran, the siRNA that disrupts LPA gene expression, have shown sustained reductions in Lp(a) levels nearly a year after their last dose.
Other articles available on Lp(a) Forum
